|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|PE ratio (TTM)||16.34|
|Forward dividend & yield||0.63 (1.52%)|
|1y target est||N/A|
Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.
UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes